Skip to main content

Inauguration of a new Advancell nanomedicine laboratory at the Vida Campus of Santiago de Compostela

By 15 de June de 2010November 18th, 2020No Comments
< Back to news

Inauguration of a new Advancell nanomedicine laboratory at the Vida Campus of Santiago de Compostela

Next Friday June 18 Advancell, a biotech company –based at the Barcelona Science Park–, will be inaugurating a new nanomedicine laboratory in which the Advancell Nanosystems unit will conduct its activity. The new laboratory is located in the Emprendia Building and boasts a surface of over 300 m2 that will be divided into three main areas: a research room, where nanocapsules will be produced in accord with the technology used; a study room, which will primarily host the study of the active principle; and a production room, where, once the prototype has been produced at a small scale (within a 10 to 250 gram range), it will be converted into a larger scale of up to 5 Kg.

Important politicians, institutional and academic representatives, including the councilor of Social Services of the Santiago de Compostela city council, Mar Martín, the general director of Research, Development and Innovation, Ricardo Capilla Pueyo, the subdelegate of the Government in the province of A Coruña, Jose Manual Pose Mesura, the professor of Pharmacy María José Alonso, who is also the main author of Advancell patents in the field of nanosystems and a world renowned reference in nanomedicine; the vice-rector of Research at the USC, Francisco González, and Davide Sirtoli and Kenneth Weissmahr, president and general director of Advancell, respectively.

In addition, the renowned nanomedicine expert Patrick Couvreur, and the director of the Advancell Nanosystems unit, Ana Vila, will participate in a conference on nanomedicine and its applications.

The inauguration of this laboratory is further proof of the consolidation of biotechnology and evidence of the strong support to research and innovation, which have been defining traits of Advancell since its earliest stages. It is also a key factor to achieve the economic objectives established in the company’s strategic plan.

Over the course of the press conference, which will take place at 10.15 a.m., Davide Sirtoli, Kenneth Weissmahr and Ana Vila will explain the current projects and upcoming challenges of Advancell Nanosystems. Once the press conference has ended, attendees will visit the new laboratory and the conference “Nanomedicine: a new technology and its applications” will be held.

Advancell is a biotech company that uses its own technology and continuous innovation to respond to health- and wellbeing-related needs by providing efficient and added value products and services. The company thrives from findings in the academic setting in order to improve and develop them in the market. The company is divided into three business units: Advancell Therapeutics, which focuses its activity on the development of innovative drugs up to their clinical concept testing phase by means of the research of new applications for known molecules; Advancell Alternative Testing, which uses cell-based in vitro methods to predict the efficacy, safety and the mechanism of actions of molecules that are under development, and Advancell Nanosystems, which uses nanomedicine to treat and prevent diseases.

Advancell’s business model enables a considerable reduction of costs, risks and the time needed to develop the drug. Its projects in clinical phase focus on nanomedicines for the treatment of psoriasis (in collaboration with the ISDIN), on the development of a new orphan drug for Chronic Lymphocytic Leukemia and on a topical formulation for the treatment of Plantar Palmar Erythrodysesthesia (ATH008). The company is based at the Barcelona Science Park and has research centers at the University of Santiago de Compostela and in the La Fe Hospital of Valencia.